On June 27, 2018, the Canadian Agency for Drugs and Technologies in Health (CADTH) published new guidelines, Procedure and Submission Guidelines for the CADTH Common Drug Review, which consolidate two previously separate guidelines and include a number of revisions to the submission requirements. These changes are summarized in CDR Update – Issue 138, and will be enforced for all submissions and resubmissions received on or after July 27, 2018.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.








